Cargando…

Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience

AIM: To assess clinicopathological features and outcomes in patients of primary gliosarcoma with changing trends of treatment. MATERIALS AND METHODS: Medical records were reviewed and data collected on primary gliosarcoma over a 5-year period (2009–2013) from the departmental case files. RESULTS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Narendra, Bhattacharyya, Tapesh, Chanchalani, Karan, Shalunke, Praveen, Radotra, B D, Yadav, Budhi Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382775/
https://www.ncbi.nlm.nih.gov/pubmed/25839013
http://dx.doi.org/10.4103/2278-330X.149931
_version_ 1782364631102128128
author Kumar, Narendra
Bhattacharyya, Tapesh
Chanchalani, Karan
Shalunke, Praveen
Radotra, B D
Yadav, Budhi Singh
author_facet Kumar, Narendra
Bhattacharyya, Tapesh
Chanchalani, Karan
Shalunke, Praveen
Radotra, B D
Yadav, Budhi Singh
author_sort Kumar, Narendra
collection PubMed
description AIM: To assess clinicopathological features and outcomes in patients of primary gliosarcoma with changing trends of treatment. MATERIALS AND METHODS: Medical records were reviewed and data collected on primary gliosarcoma over a 5-year period (2009–2013) from the departmental case files. RESULTS: A total 27 patients were included in this study. The median age of presentation was 54 years. There was a slight male preponderance, with male to female ratio of 1.25:1. The most common location of the tumor was temporal lobe (44.4%). Gross total resection was possible in 19 cases, near total excision was done in five cases, and only partial excision with decompression in three cases. Of the 27 patients, 80.8% patients received post-operative radical external beam radiotherapy of 60 Gy/30#/6 weeks. Concurrent and adjuvant temozolomide was used in 42.3% cases, depending on affordability and tolerance. Median overall survival was 9 months. On subgroup analysis, median overall survival in the radiotherapy plus temozolomide group was 10 months as compared to 9 months in the radiotherapy alone group; however, this was not statistically significant.(P = 0.244). CONCLUSION: Treating Gliosarcoma is a major therapeutic challenge for a clinician because of its poor prognosis, aggressive clinical behavior, rarity, and limited clinical experience. With surgery and concurrent chemoradiation, we were able to achieve a median overall survival of 9 months. Addition of temozolomide has shown a better trend in survival though it is not statistically significant.
format Online
Article
Text
id pubmed-4382775
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-43827752015-04-02 Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience Kumar, Narendra Bhattacharyya, Tapesh Chanchalani, Karan Shalunke, Praveen Radotra, B D Yadav, Budhi Singh South Asian J Cancer NEURO-ONCOLOGY: Original Article AIM: To assess clinicopathological features and outcomes in patients of primary gliosarcoma with changing trends of treatment. MATERIALS AND METHODS: Medical records were reviewed and data collected on primary gliosarcoma over a 5-year period (2009–2013) from the departmental case files. RESULTS: A total 27 patients were included in this study. The median age of presentation was 54 years. There was a slight male preponderance, with male to female ratio of 1.25:1. The most common location of the tumor was temporal lobe (44.4%). Gross total resection was possible in 19 cases, near total excision was done in five cases, and only partial excision with decompression in three cases. Of the 27 patients, 80.8% patients received post-operative radical external beam radiotherapy of 60 Gy/30#/6 weeks. Concurrent and adjuvant temozolomide was used in 42.3% cases, depending on affordability and tolerance. Median overall survival was 9 months. On subgroup analysis, median overall survival in the radiotherapy plus temozolomide group was 10 months as compared to 9 months in the radiotherapy alone group; however, this was not statistically significant.(P = 0.244). CONCLUSION: Treating Gliosarcoma is a major therapeutic challenge for a clinician because of its poor prognosis, aggressive clinical behavior, rarity, and limited clinical experience. With surgery and concurrent chemoradiation, we were able to achieve a median overall survival of 9 months. Addition of temozolomide has shown a better trend in survival though it is not statistically significant. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4382775/ /pubmed/25839013 http://dx.doi.org/10.4103/2278-330X.149931 Text en Copyright: © South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle NEURO-ONCOLOGY: Original Article
Kumar, Narendra
Bhattacharyya, Tapesh
Chanchalani, Karan
Shalunke, Praveen
Radotra, B D
Yadav, Budhi Singh
Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience
title Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience
title_full Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience
title_fullStr Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience
title_full_unstemmed Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience
title_short Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience
title_sort impact of changing trends of treatment on outcome of cerebral gliosarcoma: a tertiary care centre experience
topic NEURO-ONCOLOGY: Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382775/
https://www.ncbi.nlm.nih.gov/pubmed/25839013
http://dx.doi.org/10.4103/2278-330X.149931
work_keys_str_mv AT kumarnarendra impactofchangingtrendsoftreatmentonoutcomeofcerebralgliosarcomaatertiarycarecentreexperience
AT bhattacharyyatapesh impactofchangingtrendsoftreatmentonoutcomeofcerebralgliosarcomaatertiarycarecentreexperience
AT chanchalanikaran impactofchangingtrendsoftreatmentonoutcomeofcerebralgliosarcomaatertiarycarecentreexperience
AT shalunkepraveen impactofchangingtrendsoftreatmentonoutcomeofcerebralgliosarcomaatertiarycarecentreexperience
AT radotrabd impactofchangingtrendsoftreatmentonoutcomeofcerebralgliosarcomaatertiarycarecentreexperience
AT yadavbudhisingh impactofchangingtrendsoftreatmentonoutcomeofcerebralgliosarcomaatertiarycarecentreexperience